View options
Result details

Results per page
Articles per page View Sort by

4 results matched your search query
Keywords = Malignant

  • Open Access Case Report
    Export citation: APA   BibTeX   EndNote   RIS  
    Trends Journal of Sciences Research 2018, 3(2), 96-103. http://doi.org/10.31586/Surgery.0302.06
    42 Views 51 Downloads PDF Full-text (2.387 MB)  HTML Full-text
    Abstract
    Primary cardiac tumors are rare with an incidence ranging from 0.001% to 0.03% in autopsy series. The prognosis of cardiac sarcomas remains poor because it proliferates rapidly, and distant metastases are often found at diagnosis. We present a case of liposarcoma in the atrium of the heart as case report
    [...] Read more.
    Primary cardiac tumors are rare with an incidence ranging from 0.001% to 0.03% in autopsy series. The prognosis of cardiac sarcomas remains poor because it proliferates rapidly, and distant metastases are often found at diagnosis. We present a case of liposarcoma in the atrium of the heart as case report and same time,we do a literature review about it.Case Report: We present the case of a 30-year-old female with a significant tumor of cardiac liposarcoma, with chief complaint of dyspnea, tachycardia and heart failure even angina pectoris.Conclusion: The diagnostician?s differential diagnosis must be broad when encountering common chief complaints, such as tachycardia, heart failure and angina pectoris.  Full article
    Figures

    Figure 2 of 3

    References
    [1]
    Guilherme H. Oliveira, MD*; Sadeer G. Al-Kindi, MD*; Christopher Hoimes, DO; Soon J. Park, MD Characteristics and Survival of Malignant Cardiac Tumors A 40-Year Analysis of >500 Patients (Circulation. 2015;132:2395-2402. DOI: 10.1161/CIRCULATIONAHA.115.016418.)
    [2]
    Cristina Basso, Stefania Rizzo, Marialuisa Valente, Gaetano Thiene, Prevalence and pathology of primary cardiac tumours. Cardiovascular Medicine 2012;15(1):18?29
    [3]
    Vander Salm TJ.Unusual primary tumors of the heart. Semin Thorac Cardiovasc Surg.2000 Apr;12(2):89-100.
    [4]
    Elizabeth S. Ellent, MD,1 Ronald Chong-Yik, MD, MPH,1,2 Abdul Mukhtadir Khan, MD3. Metastatic Cardiac Angiosarcoma in a 26-Year-Old Male. Ochsner Journal 16:324?328, 2016
    [5]
    Freedom RM, Lee KJ, MacDonald C, Taylor G. Selected aspects of cardiac tumors in infancy and childhood. Pediatr Cardiol. 2000;21:299? 316.
    [6]
    Song Y, Hu R, Yao Q. Pathological analysis of 268 cases of tumors in the heart and the pericardium. J SUN Yat-sen-Univ (Med Sci) 2003;24:197? 201.
    [7]
    Roberts WC. Primary and secondary neoplasms of the heart. Am J Cardiol. 1997;80:671?82.
    [8]
    Bussani R, De-Giorgio F, Abbate A, Silvestri F. Cardiac metastasis. J Clin Pathol. 2007;60:27?34.
    [9]
    Hanfling SM. Metastatic cancer to the heart. Review of the literature and report of 127 cases. Circulation. 1960;22:474?83.
    [10]
    Thomas-de-Montpr?ville V, Nottin R, Dulmet E, Serraf A. Heart tumors in children and adults: clinicopathological study of 59 patients from a surgical center. Cardiovasc Pathol. 2007;16:22?8.
    [11]
    Bussani R, De-Giorgio F, Abbate A, Silvestri F. Cardiac metastasis. J Clin Pathol. 2007;60:27?34.
    [12]
    Travis WT, Brambilla E, Muller-Hermelink HK, Harris CC, eds. Pathology and genetics of tumours of the lung, pleura and heart. World Health Organisation Classification of tumours. Lyon: IARC; 2004.
    [13]
    Reynen K. Cardiac myxomas. N Engl J Med. 1995;33:1610?7.
    [14]
    Basso C, Valente M, Casarotto D, Thiene G. Cardiac lithomyxoma. Am J Cardiol. 1997;80:1249?51.
    [15]
    Burke AP, Virmani R. Cardiac myxoma: a clinicopathologic study. Am J Clin Pathol. 1993;100:671?80.
    [16]
    Edwards FH, Hale D, Cohen A, Thompson L, Pezzella AT, Virmani R. Primary cardiac valve tumors. Ann Thorac Surg. 1991;52:1127?31.
    [17]
    Sun JP, Asher CR, Yang XS, Cheng GG, Scalia GM, Massed AG, et al. Clinical and echocardiographic characteristics of papillary fibroelastomas: a retrospective and prospective study in 162 patients. Circulation. 2001;103:2687?93.
    [18]
    Basso C, Bottio T, Valente M, Bonato R, Casarotto D, Thiene G. Primary cardiac valve tumours. Heart. 2003;89:1259?60.
    [19]
    Gowda RM, Khan IA, Nair CK, Mehta NJ, Vasavada BC, Sacchi TJ. Cardiac papillary fibroelastoma: a comprehensive analysis of 725 cases. Am Heart J. 2003;146:404?10.
    [20]
    Valente M, Basso C, Thiene G, Bressan M, Stritoni P, Cocco P, Fasoli G. Fibroelastic papilloma: a not-so-benign cardiac tumor. Cardiovasc Pathol. 1992;1:161?6.
    [21]
    Cunningham KS, Veinot JP, Feindel CM, Butany J. Fatty lesions of the atria and interatrial septum. Hum Pathol. 2006;37:1245?51.
    [22]
    Brizard C, Latremouille C, Jebara VA, Acar C, Fabiani JN, Carpentier AF. Cardiac hemangiomas. Ann Thorac Surg. 1993;56:390?4.
    [23]
    Kipfer B, Englberger L, Stauffer E, Carrel T. Rare presentation of cardiac hemangiomas. Ann Thorac Surg. 2000;70:977?9.
    [24]
    Uzun O, Wilson DG, Vujanic GM, Parsons JM, De Giovanni JV. Cardiac tumours in children. Orphanet J Rare Dis. 2007;2:11.
    [25]
    Chan HSL, Sonley MJ, Moes CAF, Daneman A, Smith CR, Martin DJ. Primary and secondary tumors of childhood involving the heart, pericardium and great vessels. A report of 75 cases and review of the literature. Cancer. 1985;56:825?36.
    [26]
    Beghetti M, Gow RM, Haney I, Maswon J, Williams WG, Freedom RM. Pediatric primary benign cardiac tumors: a 15-year review. Am Heart J. 1997;134:1107?14.
    [27]
    Becker, Anton E. Primary heart tumors in the pediatric age group: a review of salient pathologic features relevant for clinicians. Pediatr Cardiol. 2000;21:317?23.
    [28]
    Padalino MA, Basso C, Milanesi O, Vida VL, Moreolo GS, Thiene G, Stellin G. Surgically treated primary cardiac tumors in early infancy and childhood. J Thorac Cardiovasc Surg. 2005;129:1358?63.
    [29]
    Nir A, Tajik J, Freeman WK, et al. Tuberous sclerosis and cardiac rhabdomyoma. Am J Cardiol. 1995;76:419?21.
    [30]
    Kurian KK, Weisshaar D, Parekh H et al. Primary angiosarcoma: case report and review of the literature. Cardiovascular Pathology, 2006;15:110?2
    [31]
    Thiene G, Valente M, Lombardi M, Basso C. Tumours of the Heart. In: Camm JA, Luscher TF, Serruys PV, eds. ESC Textbook of Cardiovascular Medicine. Oxford: University Press; 2009.
    [32]
    Van Veer H, Meuris B, Verbeken E, Herijgers P. Primary atrial fibrosarcoma of the heart. Cardiovasc Pathol. 2008;17:325?8.
    [33]
    Basso C, Stefani A, Calabrese F, Fasoli G, Valente M. Primary atrial fibrosarcoma diagnosed by endocardial biopsy. Am Heart J. 1996;131:399? 402.
    [34]
    Mazzola A, Spano JP, Valente M, Gregorini R, Villani C, Di Eusanio M, et al. Leiomyosarcoma of the left atrium mimicking a left atrial myxoma. J Thorac Cardiovasc Surg. 2006;131:224?6.
    [35]
    Mazzucco A, Luciani GB, Bertolini P, Faggian G, Morando G, Ghimenton C. Primary leiomyosarcoma of the pulmonary artery: diagnostic and surgical implications. Ann Thorac Surg. 1994;57:222?5.
    [36]
    Burke AP, Rosada-de Christenson ML, Templeton PA, Virmani R. Cardiac fibroma: clinicopathologic correlates and surgical treatment. J Thorac Cardiovasc Surg. 1994;108:862?70
    [37]
    Warren WH. Malignancies involving the pericardium. Semin Thorac Cardiovasc Surg. 2000;12:119?29.
    [38]
    Luk A, Ahn E, Vaideeswar P, Butany JW. Pericardial tumors. Semin Diagn Pathol. 2008;25:47?53.
    [39]
    Bendek M, Ferenc M, Freudenberg N. Post-irradiation pericardial malignant mesothelioma: an autopsy case and review of the literature. Cardiovasc Pathol. 2010;19:377?9.
    [40]
    Yoshiyuki Yamashita, Kazuhiro Kurisu, Satoshi Kimura, and Yasutaka Ueno. Successful resection of a huge metastatic liposarcoma in the pericardium resulting in improvement of diastolic heart failure: a case report. Surg Case Rep. 2015 Dec; 1: 74. Published online 2015 Sep 2. doi: 10.1186/s40792-015-0079-4
    [41]
    Conklin LD, Reardon MJ. Autotransplantation of the heart for primary cardiac malignancy: development and surgical technique. Texas Heart Institute Journal. 2002;29(2):105.
  • Open Access Research Article
    Export citation: APA   BibTeX   EndNote   RIS  
    Trends Journal of Sciences Research 2018, 3(4), 161-169. http://doi.org/10.31586/Biomedicine.0304.03
    54 Views 66 Downloads PDF Full-text (1.915 MB)  HTML Full-text
    Abstract
    Background: Hepatocellular carcinoma is one of the most common malignant tumors, with rapid development and high malignancy. MicroRNAs have been reported to play important roles in hepatocellular carcinoma progression. Aim: To identify the key genes and miRNAs in HCC, and to explore their potential molecular mechanisms. Methods: Gene expression profiles
    [...] Read more.
    Background: Hepatocellular carcinoma is one of the most common malignant tumors, with rapid development and high malignancy. MicroRNAs have been reported to play important roles in hepatocellular carcinoma progression. Aim: To identify the key genes and miRNAs in HCC, and to explore their potential molecular mechanisms. Methods: Gene expression profiles of GSE15471 (mRNA profile) and GSE57555 (miRNA profile) were downloaded from gene expression omnibus, which were analysed using R software and bioconductor packages. The gene ontology and Kyoto Encyclopedia of Genes and Genomes pathway enrichments of DEGs were performed using the DAVID database, and the protein–protein interaction networks of the DEGs were constructed from the STRING database. In addition, targets of differentially expressed miRNAs were predicted by the online resource miRDB. Result: In total, 191 differentially expressed genes were identified, including 142 upregulated and 49 downregulated genes. Functional analysis revealed that these DEGs were associates with wound healing, endodermal cell-cell adhesion, activation of MAPK activity and negative regulation of cell proliferation. In addition, we identified five DEMs, which were upregulated and downregulated. hsa-miR-122-5p may target the PDK4, and hsa-miR-21-5p probably targets SPOCK1 and PAIP2B. Conclusions: We applied integrated bioinformatics to identify key pathogenic genes involved in hepatocellular carcinoma and provide new clues for further studies of hepatocellular carcinoma.  Full article
    Figures

    Figure 4 of 4

    References
    [1]
    Feng Y, Zu LL, Zhang L. MicroRNA-26b inhibits the tumor growth of human liver cancer through the PI3K/Akt and NF-kappaB/MMP-9/VEGF pathways. Oncol Rep. 2018;39(5):2288-96.
    [2]
    Liu H, Cheng L, Cao D, Zhang H. Suppression of miR-21 Expression Inhibits Cell Proliferation and Migration of Liver Cancer Cells by Targeting Phosphatase and Tensin Homolog (PTEN). Med Sci Monit. 2018;24:3571-7.
    [3]
    Grainger S, Traver D, Willert K. Wnt Signaling in Hematological Malignancies. Prog Mol Biol Transl Sci. 2018;153:321-41.
    [4]
    Setshedi M, Andersson M, Kgatle MM, Roberts L. Molecular and cellular oncogenic mechanisms in hepatocellular carcinoma. S Afr Med J. 2018;108(8b):41-6.
    [5]
    Kroemer G, Pouyssegur J. Tumor cell metabolism: cancer's Achilles' heel. Cancer cell. 2008;13(6):472-82.
    [6]
    Lu X, Kang Y. Hypoxia and hypoxia-inducible factors: master regulators of metastasis. Clin Cancer Res. 2010;16(24):5928-35.
    [7]
    Guo JR, Shen HC, Liu Y, Xu F, Zhang YW, Shao Y, et al. Effect of Acute Normovolemic Hemodilution Combined with Controlled Low Central Venous Pressure on Blood Coagulation Function and Blood Loss in Patients Undergoing Resection of Liver Cancer Operation. Hepatogastroenterology. 2015;62(140):992-6.
    [8]
    Sang L, Wang XM, Xu DY, Zhao WJ. Bioinformatics analysis of aberrantly methylated-differentially expressed genes and pathways in hepatocellular carcinoma. World J Gastroenterol. 2018;24(24):2605-16.
    [9]
    He JH, Han ZP, Wu PZ, Zou MX, Wang L, Lv YB, et al. Gene-gene interaction network analysis of hepatocellular carcinoma using bioinformatic software. Oncol Lett. 2018;15(6):8371-7.
    [10]
    Dang S, Zhou J, Wang Z, Wang K, Dai S, He S. MiR-299-3p functions as a tumor suppressor via targeting Sirtuin 5 in hepatocellular carcinoma. Biomed Pharmacother. 2018;106:966-75.
    [11]
    Wakasugi H, Takahashi H, Niinuma T, Kitajima H, Oikawa R, Matsumoto N, et al. Dysregulation of miRNA in chronic hepatitis B is associated with hepatocellular carcinoma risk after nucleos(t)ide analogue treatment. Cancer Lett. 2018;434:91-100.
    [12]
    Li Z, Xue TQ, Yang C, Wang YL, Zhu XL, Ni CF. EGFL7 promotes hepatocellular carcinoma cell proliferation and inhibits cell apoptosis through increasing CKS2 expression by activating Wnt/beta-catenin signaling. J Cell Biochem. 2018;10.1002
    [13]
    Yan L, Xu F, Dai CL. Relationship between epithelial-to-mesenchymal transition and the inflammatory microenvironment of hepatocellular carcinoma. J Exp Clin Cancer Res. 2018;37(1):203.
    [14]
    Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman K, et al. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev. 2001;22(2):153-83.
    [15]
    Li D, Ren W, Jiang Z, Zhu L. Regulation of the NLRP3 inflammasome and macrophage pyroptosis by the p38 MAPK signaling pathway in a mouse model of acute lung injury. Mol Med Rep. 2018.
    [16]
    Si L, Xu L, Yin L, Qi Y, Han X, Xu Y, et al. Potent effects of dioscin against pancreatic cancer via miR-149-3P-mediated inhibition of the Akt1 signalling pathway. Br J Pharmacol. 2017;174(7):553-68.
    [17]
    Lee RC, Ambros V. An extensive class of small RNAs in Caenorhabditis elegans. Science. 2001;294(5543):862-4.
    [18]
    Woolbright BL, Choudhary D, Mikhalyuk A, Trammel C, Shanmugam S, Abbott E, et al. The Role of Pyruvate Dehydrogenase Kinase-4 (PDK4) in Bladder Cancer and Chemoresistance. Mol Cancer Ther. 2018;17(9):2004-12.
    [19]
    Sun S, Liu J, Zhao M, Han Y, Chen P, Mo Q, et al. Loss of the novel mitochondrial protein FAM210B promotes metastasis via PDK4-dependent metabolic reprogramming. Cell Death Dis. 2017;8(6):e2870.
    [20]
    Choiniere J, Wu J, Wang L. Pyruvate Dehydrogenase Kinase 4 Deficiency Results in Expedited Cellular Proliferation through E2F1-Mediated Increase of Cyclins. Mol Pharmacol. 2017;91(3):189-96.
    [21]
    Han H, Li W, Shen H, Zhang J, Zhu Y, Li Y. microRNA-129-5p, a c-Myc negative target, affects hepatocellular carcinoma progression by blocking the Warburg effect. J Mol Cell Biol. 2016.
    [22]
    Yang J, Yang Q, Yu J, Li X, Yu S, Zhang X. SPOCK1 promotes the proliferation, migration and invasion of glioma cells through PI3K/AKT and Wnt/beta-catenin signaling pathways. Oncol Rep. 2016;35(6):3566-76.
    [23]
    Chen D, Zhou H, Liu G, Zhao Y, Cao G, Liu Q. SPOCK1 promotes the invasion and metastasis of gastric cancer through Slug-induced epithelial-mesenchymal transition. J Cell Mol Med. 2018;22(2):797-807.
    [24]
    Veenstra VL, Damhofer H, Waasdorp C, Steins A, Kocher HM, Medema JP, et al. Stromal SPOCK1 supports invasive pancreatic cancer growth. Mol Oncol. 2017;11(8):1050-64.
    [25]
    Kachaev ZM, Lebedeva LA, Kozlov EN, Toropygin IY, Schedl P, Shidlovskii YV. Paip2 is localized to active promoters and loaded onto nascent mRNA in Drosophila. Cell Cycle. 2018;17(14):1708-20.
    [26]
    Rosenfeld AB. Suppression of cellular transformation by poly (A) binding protein interacting protein 2 (Paip2). PLoS One. 2011;6(9):e25116.
  • Open Access Research Article
    Export citation: APA   BibTeX   EndNote   RIS  
    Trends Journal of Sciences Research 2019, 4(3), 121-126. http://doi.org/10.31586/Cancer.0403.05
    39 Views PDF Full-text (1.028 MB)  HTML Full-text
    Abstract
    Background and objective: Glioblastoma (GBM) is one of the malignant tumors causing death worldwide. Most patients were found in the middle and late stages and had poor prognosis. The purpose of this study was to investigate the expression and significance of CTSC in GBM. Methods: The information about CTSC in
    [...] Read more.
    Background and objective: Glioblastoma (GBM) is one of the malignant tumors causing death worldwide. Most patients were found in the middle and late stages and had poor prognosis. The purpose of this study was to investigate the expression and significance of CTSC in GBM. Methods: The information about CTSC in Oncomine database was collected and analyzed twice. The role of CTSC in GBM was meta-analyzed. The expression of CTSC in glioma cell lines was retrieved by CCLE database, and the survival of patients was analyzed by TCGA database. Results: A total of 1,459 different types of CTSC were collected in Oncomine database, 134 of which had statistical differences in CTSC expression, 89 of which had increased CTSC expression and 45 of which had decreased CTSC expression. A total of 50 studies involving the expression of CTSC in GBM cancer and normal tissues included 1,189 samples. Compared with the control group, CTSC was highly expressed in GBM (P < 0.05). Moreover, CTSC was highly expressed in glioma cell lines. There was a correlation between the expression of CTSC and the overall survival rate of GBM. The overall survival rate of patients with high expression of CTSC was worse, while the prognosis of patients with low expression of CTSC was better (P < 0.05). Conclusion: Through the in-depth mining of oncomine gene chip database, we propose that CTSC is highly expressed in GBM tissues and is related to the prognosis of GBM, which may provide an important theoretical basis for the treatment of glioma..  Full article
    Figures

    Figure 1 of 4

    Figures

    Figure 1 of 4

    References
    [1]
    Kirkpatrick JP, Laack NN, Shih HA, Gondi V. Management of GBM: a problem of local recurrence. J Neurooncol 2017;134:487-93.
    [2]
    Jayaraman A, Jamil K, Khan HA. Identifying new targets in leukemogenesis using computational approaches. Saudi J Biol Sci 2015;22:610-22.
    [3]
    Hou W, Sun H, Ma Y, Liu C, Zhang Z. Identification and Optimization of Novel Cathepsin C Inhibitors Derived from EGFR Inhibitors. J Med Chem 2019.
    [4]
    Fan W, Zhang W, Alshehri S, Neeley TR, Garrison JC. Enhanced tumor retention of NTSR1-targeted agents by employing a hydrophilic cysteine cathepsin inhibitor. Eur J Med Chem 2019;177:386-400.
    [5]
    Shoaib M, Ansari AA, Haq F, Ahn SM. IPCT: Integrated Pharmacogenomic Platform of Human Cancer Cell Lines and Tissues. Genes (Basel) 2019;10.
    [6]
    Goswami CP, Nakshatri H. PROGgeneV2: enhancements on the existing database. BMC Cancer 2014;14:970.
    [7]
    Tang Y, He W, Wei Y, Qu Z, Zeng J, Qin C. Screening key genes and pathways in glioma based on gene set enrichment analysis and meta-analysis. J Mol Neurosci 2013;50:324-32.
    [8]
    Zuo X, Hou Q, Jin J, et al. Inhibition of Cathepsins B Induces Neuroprotection Against Secondary Degeneration in Ipsilateral Substantia Nigra After Focal Cortical Infarction in Adult Male Rats. Front Aging Neurosci 2018;10:125.
    [9]
    Lupo KB, Matosevic S. Natural Killer Cells as Allogeneic Effectors in Adoptive Cancer Immunotherapy. Cancers (Basel) 2019;11.
    [10]
    Yan H, Zhou HF, Akk A, et al. Neutrophil Proteases Promote Experimental Abdominal Aortic Aneurysm via Extracellular Trap Release and Plasmacytoid Dendritic Cell Activation. Arterioscler Thromb Vasc Biol 2016;36:1660-9.
    [11]
    Doughty MJ, Gruenstein EI. Cell growth and substrate effects on characteristics of a lysosomal enzyme (cathepsin C) in Duchenne muscular dystrophy fibroblasts. Biochem Cell Biol 1987;65:617-25.
    [12]
    Gelman BB, Papa L, Davis MH, Gruenstein E. Decreased lysosomal dipeptidyl aminopeptidase I activity in cultured human skin fibroblasts in Duchenne's muscular dystrophy. J Clin Invest 1980;65:1398-406.
    [13]
    Ruffell B, Affara NI, Cottone L, et al. Cathepsin C is a tissue-specific regulator of squamous carcinogenesis. Genes Dev 2013;27:2086-98.
  • Open Access Research Article
    Export citation: APA   BibTeX   EndNote   RIS  
    Trends Journal of Sciences Research 2019, 4(3), 121-126. http://doi.org/10.31586/Cancer.0403.05
    39 Views PDF Full-text (1.028 MB)  HTML Full-text
    Abstract
    Background and objective: Glioblastoma (GBM) is one of the malignant tumors causing death worldwide. Most patients were found in the middle and late stages and had poor prognosis. The purpose of this study was to investigate the expression and significance of CTSC in GBM. Methods: The information about CTSC in
    [...] Read more.
    Background and objective: Glioblastoma (GBM) is one of the malignant tumors causing death worldwide. Most patients were found in the middle and late stages and had poor prognosis. The purpose of this study was to investigate the expression and significance of CTSC in GBM. Methods: The information about CTSC in Oncomine database was collected and analyzed twice. The role of CTSC in GBM was meta-analyzed. The expression of CTSC in glioma cell lines was retrieved by CCLE database, and the survival of patients was analyzed by TCGA database. Results: A total of 1,459 different types of CTSC were collected in Oncomine database, 134 of which had statistical differences in CTSC expression, 89 of which had increased CTSC expression and 45 of which had decreased CTSC expression. A total of 50 studies involving the expression of CTSC in GBM cancer and normal tissues included 1,189 samples. Compared with the control group, CTSC was highly expressed in GBM (P < 0.05). Moreover, CTSC was highly expressed in glioma cell lines. There was a correlation between the expression of CTSC and the overall survival rate of GBM. The overall survival rate of patients with high expression of CTSC was worse, while the prognosis of patients with low expression of CTSC was better (P < 0.05). Conclusion: Through the in-depth mining of oncomine gene chip database, we propose that CTSC is highly expressed in GBM tissues and is related to the prognosis of GBM, which may provide an important theoretical basis for the treatment of glioma..  Full article
    Figures

    Figure 1 of 4

    Figures

    Figure 1 of 4

    References
    [1]
    Kirkpatrick JP, Laack NN, Shih HA, Gondi V. Management of GBM: a problem of local recurrence. J Neurooncol 2017;134:487-93.
    [2]
    Jayaraman A, Jamil K, Khan HA. Identifying new targets in leukemogenesis using computational approaches. Saudi J Biol Sci 2015;22:610-22.
    [3]
    Hou W, Sun H, Ma Y, Liu C, Zhang Z. Identification and Optimization of Novel Cathepsin C Inhibitors Derived from EGFR Inhibitors. J Med Chem 2019.
    [4]
    Fan W, Zhang W, Alshehri S, Neeley TR, Garrison JC. Enhanced tumor retention of NTSR1-targeted agents by employing a hydrophilic cysteine cathepsin inhibitor. Eur J Med Chem 2019;177:386-400.
    [5]
    Shoaib M, Ansari AA, Haq F, Ahn SM. IPCT: Integrated Pharmacogenomic Platform of Human Cancer Cell Lines and Tissues. Genes (Basel) 2019;10.
    [6]
    Goswami CP, Nakshatri H. PROGgeneV2: enhancements on the existing database. BMC Cancer 2014;14:970.
    [7]
    Tang Y, He W, Wei Y, Qu Z, Zeng J, Qin C. Screening key genes and pathways in glioma based on gene set enrichment analysis and meta-analysis. J Mol Neurosci 2013;50:324-32.
    [8]
    Zuo X, Hou Q, Jin J, et al. Inhibition of Cathepsins B Induces Neuroprotection Against Secondary Degeneration in Ipsilateral Substantia Nigra After Focal Cortical Infarction in Adult Male Rats. Front Aging Neurosci 2018;10:125.
    [9]
    Lupo KB, Matosevic S. Natural Killer Cells as Allogeneic Effectors in Adoptive Cancer Immunotherapy. Cancers (Basel) 2019;11.
    [10]
    Yan H, Zhou HF, Akk A, et al. Neutrophil Proteases Promote Experimental Abdominal Aortic Aneurysm via Extracellular Trap Release and Plasmacytoid Dendritic Cell Activation. Arterioscler Thromb Vasc Biol 2016;36:1660-9.
    [11]
    Doughty MJ, Gruenstein EI. Cell growth and substrate effects on characteristics of a lysosomal enzyme (cathepsin C) in Duchenne muscular dystrophy fibroblasts. Biochem Cell Biol 1987;65:617-25.
    [12]
    Gelman BB, Papa L, Davis MH, Gruenstein E. Decreased lysosomal dipeptidyl aminopeptidase I activity in cultured human skin fibroblasts in Duchenne's muscular dystrophy. J Clin Invest 1980;65:1398-406.
    [13]
    Ruffell B, Affara NI, Cottone L, et al. Cathepsin C is a tissue-specific regulator of squamous carcinogenesis. Genes Dev 2013;27:2086-98.
Filter options
Publication Date
From to
Refine Publication Date
Subject Areas
Refine Subjects
Article Types
Refine Article Types
Countries / Territories
Refine Countries / Territories